Premium
Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue
Author(s) -
Jendle J.,
Nauck M. A.,
Matthews D. R.,
Frid A.,
Hermansen K.,
Düring M.,
Zdravkovic M.,
Strauss B. J.,
Garber A. J.
Publication year - 2009
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/j.1463-1326.2009.01158.x
Subject(s) - liraglutide , metformin , glimepiride , medicine , type 2 diabetes , endocrinology , placebo , adipose tissue , exenatide , diabetes mellitus , alternative medicine , pathology
Aim : The effect on body composition of liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue, as monotherapy or added to metformin was examined in patients with type 2 diabetes (T2D). Methods : These were randomized, double‐blind, parallel‐group trials of 26 [Liraglutide Effect and Action in Diabetes‐2 (LEAD‐2)] and 52 weeks (LEAD‐3). Patients with T2D, aged 18–80 years, body mass index (BMI) ≤40 kg/m 2 (LEAD‐2), ≤45 kg/m 2 (LEAD‐3) and HbA1c 7.0–11.0% were included. Patients were randomized to liraglutide 1.8, 1.2 or 0.6 mg/day, placebo or glimepiride 4 mg/day, all combined with metformin 1.5–2 g/day in LEAD‐2 and to liraglutide 1.8, 1.2 or glimepiride 8 mg/day in LEAD‐3. LEAD‐2/3: total lean body tissue, fat tissue and fat percentage were measured. LEAD‐2: adipose tissue area and hepatic steatosis were assessed. Results : LEAD‐2: fat percentage with liraglutide 1.2 and 1.8 mg/metformin was significantly reduced vs. glimepiride/metformin (p < 0.05) but not vs. placebo. Visceral and subcutaneous adipose tissue areas were reduced from baseline in all liraglutide/metformin arms. Except with liraglutide 0.6 mg/metformin, reductions were significantly different vs. changes seen with glimepiride (p < 0.05) but not with placebo. Liver‐to‐spleen attenuation ratio increased with liraglutide 1.8 mg/metformin possibly indicating reduced hepatic steatosis. LEAD‐3: reductions in fat mass and fat percentage with liraglutide monotherapy were significantly different vs. increases with glimepiride (p < 0.01). Conclusion : Liraglutide (monotherapy or added to metformin) significantly reduced fat mass and fat percentage vs. glimepiride in patients with T2D.